Eagle Pharmaceuticals, the predominantly 505(b)(2) hybrid new drug application player, says it is open to further development for complex abbreviated new drug application products, as the US-based firm awaits regulatory review for its proposed generic of Endo’s $700m Vasostrict (vasopressin) injectable.
Eagle May Launch Vasopressin ‘At-Risk’ As January Trial Looms
Additional Complex ANDAs Could Be On The Radar
Eagle Pharmaceuticals is looking increasingly likely to launch its generic of Endo’s $700m Vasostrict (vasopressin) injectable ‘at risk’ amid FDA priority review for its ANDA and a delayed trial on Vasostrict intellectual property, set to take place in January next year.
More from Generics
• By
After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
More from Products
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.